medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283346; this version posted December 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Estimating Subnational Excess Mortality in Times of Pandemic An application to French *départements* in 2020

Florian Bonnet and Carlo Giovanni Camarda*

Institut national d'études démographiques (INED), Aubervilliers

December 12, 2022

Abstract

The Covid-19 pandemic did not affect sub-national regions in a uniform way. Knowledge of the impact of the pandemic on mortality at the local level is therefore an important issue for better assessing its burden. Vital statistics are now available for an increasing number of countries for 2020 and 2021, and allow the calculation of sub-national excess mortality. However, this calculation faces two important methodological challenges: (1) it requires appropriate mortality projection models; (2) small populations implies important uncertainty in the estimates, commonly neglected. We address both issues by adopting a method to forecast mortality measures. We illustrate our approach to French *départements* (NUTS 3, 95 geographical units) and produce estimates for 2020 and both sexes. Nonetheless, the proposed approach is so flexibility to allow estimation of excess mortality during Covid-19 in most demographic scenarios as well as for past pandemics.

Keywords: Covid-19 pandemic \cdot Coherent forecast \cdot Excess mortality estimation \cdot Sub-national mortality \cdot Uncertainty quantification

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. *Corresponding author: carlo-giovanni.camarda@ined.fr Address: 9 cours des Humanités, 93322 Aubervilliers - France

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283346; this version posted December 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Bonnet & Camarda It is made available undertance by North Data on the review of Pandemic

1 Introduction

Since the emergence of the disease, estimating mortality due to Covid-19 has been the object of intense research, both to guide public policies aimed at controlling the circulation of the virus, and to know the global burden of this pandemic in various countries. National health surveillance agencies were first mobilized to provide weekly or even daily death tolls attributable to Covid-19, and thus establish a rapid indicator of the impact of the pandemic [1; 2]. However, differences in data definitions among countries, time-varying collection methods, delays in reporting and diverse coverage by place of death are known issues that hinder health surveillance systems to be employed for a reliable assessment of the pandemic [3; 4].

Over the months, the regular systems of official statistics have provided information that complements and/or corrects data provided by surveillance systems, including deaths by age from all causes. These data are the basis for the construction excess mortality measures as alternative method for assessing the burden of the pandemic. Defined as "the difference between the number of deaths (from any cause) that occur during the pandemic and the number of deaths that would have occurred in the absence of the pandemic" [5, p. 85], excess mortality can also be computed on other indicators like life expectancy and standardized death rates. Measures of excess mortality have been considered the gold standard to estimate the impact of Covid-19 [6; 7] and they have been extensively adopted in the past years. Whereas some of them used pre-pandemic years as baseline mortality in the absence of Covid-19 [8; 9], others have accounted for mortality changes over time [10; 11; 12; 13; 14].

However all of these studies estimate excess mortality at the national level. This perspective generally hides large regional differences that ought to be taken into account to better inform policy makers. Hence, in recent months, many papers have attempted to estimate excess mortality at a regional level. For some of these studies, excess mortality was the difference between 2020 or 2021 regional mortality levels and pre-pandemic mortality. In this group we have [15] for Brazil, [16] and [17] for Italy, [18] for Mexico, [19] for Portugal, [20] for Spain, [21] for Sweden, [22] for Switzerland and [23] for the United States. More thoughtful accounting of the temporal change in mortality via forecasting techniques have been also proposed for estimating excess mortality at regional level. Whereas different countries have been analyzed by [24], country-specific studies have been presented using different methods and aiming to different purposes: [25] for Belgium, [26] for Ecuador, [27] for England and Wales, [28] and [29] for Italy, [30] for Latvia, [31] for Thailand and [32] for United States.

While the value of producing excess mortality measures at a fine geographic scale seems clear and timely, the methodological challenges to estimate them are numerous, and essentially related to the presence of small populations that naturally display high stochastic variation in death counts. On the one hand in this situation possible interpretations of regional differences are necessarily limited. On the other, robust, flexible and fast methods for forecasting mortality levels in the theoretical absence of a pandemic as well as for computing uncertainty around estimates become crucial.

In this study, we propose a novel approach to estimate subnational excess mortality in times of pandemic aiming to cope with all these issues in a unified and clear-cut framework. In details, we use CP-splines [33] to project mortality, since this approach exhibits two relevant features when dealing with small area mortality analysis: a large flexibility in modelling diverse demographic scenarios comes along with robustness with respect variation due to small populations at risk. Concerning

reliable measures of uncertainty around estimates for the numerous subpopulations at hands, we present a fully analytic procedure with enormous advantages from computational cost and time perspective.

To illustrate this approach, we compute excess mortality in 2020 for the 95 Metropolitan French *départements*, the finest geographical level (NUTS 3) of the classification used by Eurostat. Despite specific outcomes from France, this paper aims to provide a general framework for computing excess mortality and associated uncertainty at subnational level. Given this purpose, R routines [34] are publicly available to replicate our methodology in other countries, and in different historical contexts. See the open source framework repository on this link https://osf.io/zt2c8/?view_only=16ff2a7384c04659bdc39c6a223f2403 [Currently the link is made anonymous for peer review].

2 Methods

In this section we give an overview of the methodological aspects behind the computation of excess mortality. Specifically, we measure excess mortality accounting for both historical mortality trends and specific age-pattern in each subnational population. For ease of presentation, we focus on 2020. However, without loss of generality, computation of excess mortality in successive years can be obtained by extending the forecast horizon presented below. Moreover, we compute associated uncertainty in a simple, albeit rigorous, procedure. This allows us to separate main sources of variation before assessing any possible mortality shock in small areas.

For a given subpopulation and sex, we have $\mathbf{D} = (d_{ij})$ and $\mathbf{E} = (e_{ij})$, $m \times n$ matrices of deaths and exposures. Number of deaths d_{ij} at age *i* in year *j* are assumed to be realizations from a Poisson distribution with mean $\mu_{ij} e_{ij}$ [35], where μ_{ij} is commonly named force of mortality. In order to compute a theoretical level that would have occurred in the absence of the pandemic, we model observed mortality for n_1 pre-pandemic years and forecast μ_{ij} for 2020. Among a large number of approaches, we adopt a *CP*-spline model for forecasting mortality in 2020 [33]. This method allows us to simultaneously estimate and forecast mortality within a regression setting with enormous advantages in the computation of uncertainty measures. Let arrange the complete matrices as a column vector, that is, $\mathbf{d} = \text{vec}(\mathbf{D})$ and $\mathbf{e} = \text{vec}(\mathbf{E})$. Mortality over all ages and years can thus be expressed as the exponential of a linear combination of *B*-splines basis and coefficients:

$$\boldsymbol{\mu} = \exp\left(\boldsymbol{B}\boldsymbol{\alpha}\right)\,,\tag{1}$$

where B a two-dimensional model matrix that combines *B*-splines over age and years. The associated coefficients α are penalized to enforce smoothness over both dimensions in order to lie future 2020 mortality within trends estimated from pre-pandemic years. More details can be found in (author?) [33].

An important issue when forecasting mortality is the choice of the most appropriate period to apply the forecasting model. Instead of taking all available data or a common starting year for all regions, we optimize the time-window used for each of them. In practice, we apply CP-splines with a rolling starting year up to 2010, forecast 2019, and measure the distance between observed and forecast 2019 mortality. Working in a Poisson setting, we opt to measure distance by Deviance [36, p. 34]. The starting year with lowest Deviance value was selected for the final analysis.

A measure of excess mortality for 2020 is defined as the difference between the value of a demographic indicator in a theoretical baseline mortality level and the value for the same indicator obtained from the observed mortality. Whereas the former is obtained by CP-splines and it is solely dependent on the estimated coefficients α in (1), observed death rates $m_{2020} = d_{2020}/e_{2020}$ are the bases for computing actual level of mortality in the pandemic year.

Besides their estimated values, both observed and forecast values for any mortality measure embody levels of uncertainty that need to be accounted before drawing any conclusions about their change. This consideration is particularly relevant in subnational analyses when relatively small populations at risk are examined. Instead of time-consuming simulation and bootstrap procedures, we develop an analytic construction of the variance associated to both observed and forecast mortality indicators by delta method. With this approach, we identify and disentangle the amount of uncertainty due to either estimated baseline mortality (hereafter "forecast uncertainty") or to observed mortality level in 2020 (hereafter "Poisson uncertainty").

This general framework can be easily adapted to compute excess mortality using a large number of demographic indicators. In the Supplementary Materials A, we provide derivations to obtain these estimates and their associated uncertainty for life expectancy at any given age x, age-standardized death rates (SDRs) and plain death toll.

3 Data and applications

For illustrative purposes, we present excess mortality measures by losses/gains in life expectancy at age 60 (e_{60}) in 2020 for 95 *départements* of Metropolitan France, which correspond to the third level of the Nomenclature of Units for Territorial Statistics (NUTS) used by Eurostat. French Human Mortality Database [37] provides annual deaths (D) and population at 1st January by single age at death (with an open age interval 95+), sex, and *département* for each year between 1970 and 2020. We define exposures (E) as the mean of populations at 1st January for two consecutive years. For comparison, we gather populations and deaths to obtain data for 22 bigger *régions* (NUTS 2 level). Outcomes for this larger geographical level as well as for both sexes are provided in the Supplementary Materials B.

Figure 1 presents losses in male e_{60} for a single subpopulation, *Territoire de Belfort*. This *département* was not chosen randomly: strongly affected by the pandemic, it is a relatively small area (about 70,000 men in 2020) and therefore may show more variability in mortality due to smaller sample size.

The upper panels of Figure 1 reveals how forecast includes uncertainty around estimates. Whereas observed life expectancy at age 60 in 2020 was 21.41 years, our projected value lies between 22.95 and 23.45 years. Consequently, a loss in e_{60} is estimated between approximately 1.5 and 2 years. For comparison, Figure 1 presents what we labelled as the naive estimate of excess mortality, commonly used in many recent studies: mortality level from the 5 pre-pandemic years is used as the theoretical baseline level without pandemic. Ignoring decreasing trends in mortality, this approach biases excess mortality estimate downward: loss in e_{60} is here only 1.4 years.

The lower part of Figure 1 presents the Poisson uncertainty which is associated to the observed mortality level in 2020. Negligible when the size of the population is large, this source of uncertainty become relevant at regional level. In our example, adding the Poisson uncertainty around our estimates increases the confidence interval by 0.9 year. At last, in 2020 and for *Territoire de Belfort*,

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283346; this version posted December 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Bonnet & Camarda It is made available undertained to provide a display the preprint in Times of Pandemic



Figure 1: Illustrative figure of sources of uncertainty around excess mortality measure. Life expectancy at 60 (left panels) and associated losses (right panels) for *Territoire de Belfort*, males, 2020. Upper panels: forecast uncertainty is accounted. Lower panel: both forecast and Poisson uncertainty are reported. Texts refer to either point estimates or 95% confidence intervals. Dashed lines depict naive estimation of excess mortality.

we measure a loss in male e_{60} between 1.1 and 2.5 years.

In the Supplementary Material B we replicate Figure 1 for *Seine-Saint-Denis*. This *département* was also heavily affected by the pandemic in 2020, but male population is 13 times larger. Total uncertainty is thus much lower (0.8 year) with we estimate a loss in e_{60} between 2.4 and 3.2 years.

Figure 2 presents point estimates of losses/gains in e_{60} for each *département* along with their 95% confidence interval as well as naive estimates. Both sources of uncertainty, forecast and Poisson, are portrayed. Figure 3 mirrors this information into a French map: point estimates are portrayed and *départements* with non-significant result at the 5% level are highlighted.

In mainland France, we estimate that e_{60} has decreased by 0.77 year, whereas the naive estimate is almost two times lower (0.42). The uncertainty around this value is 0.15 year and mostly due to forecast; the Poisson uncertainty almost disappears when we deal with the whole French male population (33 million). Loss in male e_{60} remarkably vary across the subpopulations: the maximum loss was in *Seine-Saint-Denis* (2.4 years) whereas the minimum was in *Gers* (gain of 0.6 year). However, 95% confidence intervals around this point estimate is very large (1.2 years) resulting in only a slightly significant gain at the 5% level.

Overall 26 départements show not significant estimates at 5% level; only when losses in e_{60} rise to about 0.4 year we start detecting significant excess mortality, with the exception of relatively highly populated areas such as *Hérault* and *Loire-Atlantique*. Figure 3 reveals the geography of the pandemic in 2020. Whereas Western France was practically spared by the pandemic, estimates were larger in the East and in the Greater Paris (*Ile-de-France*) region with losses in life expectancy at age 60 about 1 and 1.5 years, respectively.





Figure 2: Losses in male life expectancy at age 60 in 2020 for each French *département*. Colors of dots and texts depict express the presence of significant estimates at 95% level, and colors of the horizontal bars represent the two sources of uncertainty. Green dots identify the so-called naive estimation of losses.

A central aspect of this paper concerns the importance of measuring uncertainty around excess mortality estimates when dealing with small areas. Figure 4 presents a log-log plot of the amount of uncertainty (measured by the range of the 95% confidence intervals) against population size, i.e. we portray the proportional change in uncertainty in response to a proportional change in population size. In order to broaden the view, we portray both *départements* (NUTS 3) and *régions* (NUTS 2) and, along with the total uncertainty (in green), we differentiate uncertainty coming from the forecast procedure (in purple) and from Poisson on observed data (in orange).

With a linear fit to both departmental and regional values, we are able to estimate elasticity associated to source-specific uncertainty and gauge the percent change in uncertainty for a doubling in population size. In general, we estimate that uncertainty decreases by 24% when the population doubles. This value combines two sources of uncertainty that decrease at an unequal pace when population grows. Whereas Poisson uncertainty is higher than the forecast uncertainty for almost all subnational populations, this source of uncertainty decreases at faster pace (26%) than the forecast uncertainty (17%) when the population doubles.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283346; this version posted December 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Bonnet & Camarda It is made available undertain of the author/funder is made available undertain of the preprint in the second second



Figure 3: Map of France *département* by losses/gains in male life expectancy at age 60 in 2020. Slash symbol (/) denote areas with loss/gain in e_{60} not significant at 5% level. On the upper-right corner zoom of a part of the map referring to Greater Paris (*Ile-de-France*).

We can also read Figure 4 from an alternative perspective. When excess mortality is measured by e_{60} , a loss larger than 0.75 years would be necessary to have a significant estimate at 95% level if the population size is 50,000. This value decrease with larger populations: in a region with 200,000 (one million) men, a loss in e_{60} equal to 0.4 (0.2) would be required to obtain a significant excess mortality.

4 Discussion

Assessing excess mortality during a pandemic such as the recent Covid-19 is as crucial from an health policy perspective as challenge from a methodological view. Moreover these challenges increase when we deal with excess mortality estimation at subnational level. Specifically we face two main issues.

First, computation of mortality levels that would have been observed without pandemic need to be estimated. In other words, forecasting methods are necessary to extrapolate temporal mortality variations. In this paper, we use CP-splines [33] and illustrate our approach with a reproducible example on French *départements*. If data on deaths and exposure population are available by age and year, the proposed approach is flexible to adapt to a large variety of current, and historical,

Figure 4: Log-log plot of the amount of uncertainty against population size by source of uncertainty: Total, associated to the Forecast process and due to Poisson randomness in observed data. Uncertainty is measured by the width of the 95% confidence intervals around estimated loss in male e_{60} . Values for both *départements* (NUTS 3) and *régions* (NUTS 2) are depicted. Linear fits are provided for illustrative purposes and for obtaining an approximated value of the elasticity associated to each source of uncertainty.

scenarios and robust for dealing with very small populations.

Second, uncertainty become very high when one deals with low populated areas. In this paper, we compute uncertainty around point estimates, and disentangle between uncertainty due to the forecasting process and inherent uncertainty due to Poisson random nature of observed mortality data. We show that overall uncertainty in excess mortality decreases by 24% when population doubles, though Poisson uncertainty tends to decrease more rapidly when population grows. Consequently, whereas for large populations we can safely disregard uncertainty in the observed data and account only for the forecasting errors, when dealing with excess mortality in small areas, the Poisson component in the uncertainty must be take into account before drawing any conclusions.

A possible way for reducing uncertainty, namely the Poisson component, is to either gather populations spatially by aggregating smaller administrative divisions into larger ones, or estimating excess mortality for both sexes. Still, these choices must be made with caution since associated outcomes might hide strong heterogeneity.

To illustrate these concepts Figure 5 shows densities of losses in male e_{60} for two specific French régions (lower panel) and associated lower level administrative divisions, départements (upper panel). In this example, *Ile-de-France* or Grater Paris is the région that suffered from the highest loss in life expectancy at age 60 with a 95% confidence interval loss in e_{60} of [1.57 - 1.85]. Still, this result hides large heterogeneity between the least and the harshest hit département in this région: Esonne with [0.98 - 1.68] and Seine-Saint-Denis with [2.10 - 2.70]. It is noteworthy

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283346; this version posted December 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Bonnet & Camarda It is made available undertained by Nutroation and reactions lidenstality in Times of Pandemic

Figure 5: Illustrative figure on the effects of spatial aggregation in excess mortality estimation. Densities of losses/gains in life expectancy at 60 for two NUTS 2 populations (*Ile-de-France* and *Bretagne*, lower panel) and their associated NUTS 3 populations (upper panel).

that mortality level in *Seine-Saint-Denis* was already among the highest in France before 2020. Concealing its further deterioration caused by the pandemic for the sake of reducing uncertainty by a spatial aggregation will thus be an inappropriate procedure from an health policy perspective. On the contrary, estimates for *Bretagne* do not mask large spatial heterogeneity and aggregation within this region considerably decreases size of the confidence interval around the excess mortality estimates without much loss of information.

An alternative way for reducing uncertainty keeping the same administrative division would be to combine men and women. On the one hand, practically doubling population sizes, this strategy would reduce the width of associated 95% confidence intervals by 24%. On the other estimates for both sexes will surely hide heterogeneity between men and women in a context in which literature has revealed large sex differences in Covid-19 morbidity and mortality. See, among others, [38; 39; 40; 41; 42]. For completeness, Supplementary Materials B present excess mortality estimates measured by e_{60} for both sexes combined as well as for NUTS 2 regions.

In summary, unlike most of the previous methods proposed to estimate excess mortality, our approach allows to cope with all issues akin with small populations. Thanks to its robustness, flexibility and low computational cost, we envisage its wider use for mapping the impact of Covid-19 at the international level. We also encourage national statistical offices to continue and expedite publication of mortality data at regional level that, coupled with our available routines, would facilitate a more accurate and timely assessment of the burden of any ongoing pandemic.

References

- Caporali A, Garcia J, Couppié É, Poniakina S, Barbieri M, Bonnet F, et al. The demography of COVID-19 deaths database, a gateway to well-documented international data. Scientific Data. 2022;9(1):1-9.
- [2] Riffe T, Acosta E, the COVerAGE-DB team. Data Resource Profile: COVerAGE-DB: a global demographic database of COVID-19 cases and deaths. International Journal of Epidemiology. 2021;50(2):390-390f.
- [3] Pathak EB, Garcia RB, Menard JM, Salemi JL. Out-of-hospital COVID-19 deaths: consequences for quality of medical care and accuracy of cause of death coding. American Journal of Public Health. 2021;111(S2):S101-6.
- [4] Garcia J, Torres C, Barbieri M, Cambois E, Camarda CG, Caporali A, et al. Differences in COVID-19 Mortality: the implications of imperfect and diverse data collection systems. Population. 2021;76:35-72.
- [5] Helleringer S, Queiroz BL. Commentary: Measuring excess mortality due to the COVID-19 pandemic: progress and persistent challenges. International Journal of Epidemiology. 2022;51(1):85-7.
- [6] Beaney T, Clarke JM, Jain V, Golestaneh AK, Lyons G, Salman D, et al. Excess mortality: the gold standard in measuring the impact of COVID-19 worldwide? Journal of the Royal Society of Medicine. 2020;113(9):329-34.
- [7] Karlinsky A, Kobak D. Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. eLife. 2021;10:e69336.
- [8] Mazzuco S, Campostrini S. Life expectancy drop in 2020. Estimates based on Human Mortality Database. PLoS ONE. 2022;17(1):e0262846.
- [9] Aburto JM, Schöley J, Kashnitsky I, Zhang L, Rahal C, Missov TI, et al. Quantifying impacts of the COVID-19 pandemic through life-expectancy losses: a population-level study of 29 countries. International Journal of Epidemiology. 2022;51(1):63-74.
- [10] Aburto JM, Kashyap R, Schöley J, Angus C, Ermisch J, Mills MC, et al. Estimating the burden of the Covid-19 pandemic on mortality, life expectancy and lifespan inequality in England and Wales: a population-level analysis. Journal of Epidemiology and Community Health. 2021;75(8):735-40.
- [11] Peretz C, Rotem N, Keinan-Boker L, Furshpan A, Green M, Bitan M, et al. Excess mortality in Israel associated with COVID-19 in 2020–2021 by age group and with estimates based on daily mortality patterns in 2000–2019. International Journal of Epidemiology. 2022;51(3):727-36.
- [12] Kontopantelis E, Mamas MA, Deanfield J, Asaria M, Doran T. Excess mortality in England and Wales during the first wave of the COVID-19 pandemic. Journal of Epidemiology and Community Health. 2021;75(3):213-23.
- [13] Aburto J, Schöley J, Kashnitsky I, Kashyap R. Life expectancy declines in Russia during the Covid-19 pandemic in 2020. International Journal of Epidemiology. 2022;51:1695-7.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.12.22283346; this version posted December 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Bonnet & Camarda It is made available undertanget by province to display the preprint in Times of Pandemic

- [14] Islam N, Jdanov DA, Shkolnikov VM, Khunti K, Kawachi I, White M, et al. Effects of Covid-19 pandemic on life expectancy and premature mortality in 2020: time series analysis in 37 countries. BMJ. 2021;375:e066768.
- [15] Silva GAE, Jardim BC, Santos CVBD. Excess mortality in Brazil in times of Covid-19. Ciência & Saúde coletiva. 2020;25(9):3345-54.
- [16] Gianicolo EAL, Russo A, Büchler B, Taylor K, Stang A, Blettner M. Gender specific excess mortality in Italy during the COVID-19 pandemic accounting for age. European Journal of Epidemiology. 2021;36(2):213-8.
- [17] Blangiardo M, Cameletti M, Pirani M, Corsetti G, Battaglini M, Baio G. Estimating weekly excess mortality at sub-national level in Italy during the COVID-19 pandemic. PLoS ONE. 2020;15(10):e0240286.
- [18] García-Guerrero VM, Beltrán-Sánchez H. Heterogeneity in excess of mortality and its impact on loss of life expectancy due to COVID-19: evidence from Mexico. Canadian Studies in Population. 2021;48(2-3):165-200.
- [19] Nogueira PJ, Nobre MA, Nicola PJ, Furtado C, Carneiro AV. Excess mortality estimation during the COVID-19 pandemic: preliminary data from Portugal. Acta Médica Portuguesa. 2020;33(6):450-1.
- [20] Trias-Llimós S, Riffe T, Bilal U. Monitoring life expectancy levels during the COVID-19 pandemic: Example of the unequal impact of the first wave on Spanish regions. PLoS ONE. 2020;15(11):e0241952.
- [21] Modig K, Ahlbom A, Ebeling M. Excess mortality from COVID-19: weekly excess death rates by age and sex for Sweden and its most affected region. European Journal of Public Health. 2021;31(1):17-22.
- [22] Locatelli I, Rousson V. A first analysis of excess mortality in Switzerland in 2020. PLoS One. 2021;16(6):e0253505.
- [23] Weinberger DM, Chen J, Cohen T, Crawford W Forrest, Mostashari F, Olson D, et al. Estimation of excess deaths associated with the COVID-19 pandemic in the United States, March to May 2020. JAMA Internal Medicine. 2020;180(10):1336-44.
- [24] Konstantinoudis G, Cameletti M, Gómez-Rubio V, Gómez IL, Pirani M, Baio G, et al. Regional excess mortality during the 2020 COVID-19 pandemic in five European countries. Nature communications. 2022;13(1):1-11.
- [25] Schlüter BS, Masquelier B, Camarda CG. Heterogeneity in subnational mortality in the context of the COVID-19 pandemic: the case of Belgian districts in 2020. Archives of Public Health. 2022;80(1):1-13.
- [26] Cuéllar L, Torres I, Romero-Severson E, Mahesh R, Ortega N, Pungitore S, et al. Excess deaths reveal the true spatial, temporal and demographic impact of COVID-19 on mortality in Ecuador. International Journal of Epidemiology. 2022;51(1):54-62.
- [27] Basellini U, Alburez-Gutierrez D, Del Fava E, Perrotta D, Bonetti M, Camarda CG, et al.

Linking excess mortality to mobility data during the first wave of COVID-19 in England and Wales. Social Science & Medicine - Population Health. 2021;14:100799.

- [28] Scortichini M, Schneider dos Santos R, De'Donato F, De Sario M, Michelozzi P, Davoli M, et al. Excess mortality during the COVID-19 outbreak in Italy: a two-stage interrupted time-series analysis. International Journal of Epidemiology. 2021;49(6):1909-17.
- [29] Cerqua A, Di Stefano R, Letta M, Miccoli S. Local mortality estimates during the COVID-19 pandemic in Italy. Journal of Population Economics. 2021;34(4):1189-217.
- [30] Gobiņa I, Avotins A, Kojalo U, Strele I, Pildava S, Villerusa A, et al. Excess mortality associated with the COVID-19 pandemic in Latvia: a population-level analysis of all-cause and noncommunicable disease deaths in 2020. BMC Public Health. 2022;22(1):1109.
- [31] Wilasang C, Modchang C, Lincharoen T, Chadsuthi S. Estimation of Excess All-Cause Mortality Due to COVID-19 in Thailand. Tropical Medicine and Infectious Disease. 2022;7(7):116.
- [32] Iuliano AD, Chang HH, Patel NN, Threlkel R, Kniss K, Reich J, et al. Estimating underrecognized COVID-19 deaths, United States, march 2020 - may 2021 using an excess mortality modelling approach. The Lancet Regional Health-Americas. 2021;1:100019.
- [33] Camarda CG. Smooth Constrained Mortality Forecasting. Demographic Research. 2019;41(38):1091-130.
- [34] R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2022. Available from: http://www.R-project.org.
- [35] Keiding N. Statistical Inference in the Lexis Diagram. Philosophical Transactions: Physical Sciences and Engineering. 1990;332:487-509.
- [36] McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed. Monographs on Statistics Applied Probability. London: Chapman & Hall; 1989.
- [37] Bonnet F. Computations of French lifetables by department, 1901–2014. Demographic Research. 2020;42:741-62.
- [38] Nielsen J, Nørgaard SK, Lanzieri G, Vestergaard LS, Moelbak K. Sex-differences in COVID-19 associated excess mortality is not exceptional for the COVID-19 pandemic. Scientific Reports. 2021;11:20815.
- [39] Ahrenfeldt LJ, Otavova M, Christensen K, Lindahl-Jacobsen R. Sex and age differences in COVID-19 mortality in Europe. Wiener klinische Wochenschrift. 2021;133:393-8.
- [40] Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315-20.
- [41] Pison G, Meslé F. COVID-19 is more deadly for men than for women. Population & Societies. 2022 Mar;598(3).
- [42] Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020;10(10):e040129.